ICER Enhanced Patient Engagement Program Will Be Led By Former Biopharma Exec
Yvette Venable has more than 20 years’ experience in patient advocacy, heath policy and biopharma communications.
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Stakeholders differ on whether the rapid growth in spending is to be expected, given the realities in health care and specialty drug costs, or that the data underscores the need for oversight and reform of the 340B program.
The other seven drugs on the initial list for negotiation are already heavily rebated and CMS could choose not to go much lower than current net prices, SSR Health report points out.